(Q35858331)

English

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit

scientific article published on 31 March 2014

In more languages
default for all languages
No label defined

No description defined

Statements

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit (English)
Hartmut Koeppen
Vaishali Parab
Sharianne G Louie
Ellen Filvaroff
David S Shames
Marina Lipkind
Mirella Lazarov
Vanitha Ramakrishnan
Robert L Yauch

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit